Study or Subgroup	Favours calcitonin Mean	SD	Total	Placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI
1.1.1 Short-term (1 week)								
Lyritis 1997	4.9	2.3	50	8.8	1.7	50	17.8%	-1.91 [-2.39, -1.44]
Lyritis 1991	3.94	1.71	28	6.99	1.88	28	17.0%	-1.67 [-2.29, -1.06]
Pun 1989	1.86	0.45	9	3.02	0.88	9	13.6%	-1.58 [-2.67, -0.49]
Lauro 1993	9.7	2.3	20	11.8	2.3	20	16.7%	-0.89 [-1.55, -0.24]
Tanaka 2017b	68.1	26.5	16	74.7	26.7	17	16.5%	-0.24 [-0.93, 0.44]
Tanaka 2017a	77.9	11.71	53	78.3	9.3	54	18.3%	-0.04 [-0.42, 0.34]
Subtotal (95% CI)			**176**			**178**	**100.0%**	**-1.04 [-1.79, -0.29]**
Heterogeneity: Tau^2 = 0.76; Chi^2 = 48.38, df = 5 (P < 0.00001); I^2 = 90%								
Test for overall effect: Z = 2.72 (P = 0.007)								
1.1.2 Mid-term (4 weeks)								
Pun 1989	0.38	0.19	9	1.91	0.53	9	8.5%	-3.66 [-5.30, -2.02]
Lyritis 1997	1	0.9	50	5.9	1.9	50	13.1%	-3.27 [-3.88, -2.66]
Lauro 1993	2.7	2	20	5.4	1.3	20	12.6%	-1.57 [-2.29, -0.85]
Tanaka 2017b	32.5	21.4	16	48.2	21.5	17	12.7%	-0.71 [-1.42, -0.01]
Tanaka 2017a	60.2	9.46	53	66.1	12.32	54	13.8%	-0.53 [-0.92, -0.15]
Endo 2017	37.6	21.6	114	45.1	25.9	114	14.0%	-0.31 [-0.57, -0.05]
Laroche 2006	3.1	2.76	13	3.6	2.76	14	12.5%	-0.18 [-0.93, 0.58]
Bordier 1986	35.29	20.5	15	37.93	20.2	17	12.7%	-0.13 [-0.82, 0.57]
Subtotal (95% CI)			**290**			**295**	**100.0%**	**-1.18 [-1.94, -0.43]**
Heterogeneity: Tau^2 = 1.04; Chi^2 = 100.74, df = 7 (P < 0.00001); I^2 = 93%								
Test for overall effect: Z = 3.07 (P = 0.002)								

Test for subgroup differences: Chi^2 = 0.07, df = 1 (P = 0.79), I^2 = 0%